Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (171-180 of 785) with videos related to

Pageof 79
Sort By:
Clinical Kidney Journal|October 2, 2023
Recurrent cardiovascular events in patients with type 2 diabetes and haemodialysis: analysis from the 4D StudyNikolaus Marx, Christoph Wanner, Joachim Jankowski, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severityDavid G Warnock, Giuseppe Remuzzi, Barry M Brenner, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 14, 2009
Implementation of an in vitro model system for investigation of reperfusion damage after renal ischemiaChristoph Sauvant, Reinhard Schneider, Hildegard Holzinger, et al.
Artificial Organs|January 10, 2009
Matching efficacy of online hemodiafiltration in simple hemodialysis modeDetlef H Krieter, Elisabeth Hunn, Andreas Morgenroth, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 27, 2010
Disease classification: a pitfall of the ERA/EDTA registry?Dimitrios J Tsakiris, Keith Simpson, Vianda Stel, et al.
Clinical Nephrology|August 10, 2012
Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trialMichael Koch, Dirk Henrich, Justus Faust, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 29, 2009
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitusVera Krane, Karl Winkler, Christiane Drechsler, et al.
PPAR Research|March 27, 2012
Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injuryBoris Betz, Reinhard Schneider, Tobias Kress, et al.
Therapeutics and Clinical Risk Management|February 2, 2017
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 DiabetesGuntram Schernthaner, Sarah Jarvis, Chaim Lotan, et al.
Pageof 79

Showing results (171-180 of 785) with videos related to

Sort By:
Pageof 79
Clinical Kidney Journal|October 2, 2023
Recurrent cardiovascular events in patients with type 2 diabetes and haemodialysis: analysis from the 4D StudyNikolaus Marx, Christoph Wanner, Joachim Jankowski, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severityDavid G Warnock, Giuseppe Remuzzi, Barry M Brenner, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|November 14, 2009
Implementation of an in vitro model system for investigation of reperfusion damage after renal ischemiaChristoph Sauvant, Reinhard Schneider, Hildegard Holzinger, et al.
Artificial Organs|January 10, 2009
Matching efficacy of online hemodiafiltration in simple hemodialysis modeDetlef H Krieter, Elisabeth Hunn, Andreas Morgenroth, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 27, 2010
Disease classification: a pitfall of the ERA/EDTA registry?Dimitrios J Tsakiris, Keith Simpson, Vianda Stel, et al.
Clinical Nephrology|August 10, 2012
Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trialMichael Koch, Dirk Henrich, Justus Faust, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 29, 2009
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitusVera Krane, Karl Winkler, Christiane Drechsler, et al.
PPAR Research|March 27, 2012
Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injuryBoris Betz, Reinhard Schneider, Tobias Kress, et al.
Therapeutics and Clinical Risk Management|February 2, 2017
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 DiabetesGuntram Schernthaner, Sarah Jarvis, Chaim Lotan, et al.
Pageof 79